Reduced Incidence of New-Onset Posttransplantation Diabetes Mellitus During the Last Decade
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A previous study (1995-1996) of 173 nondiabetic renal transplant recipients (historical cohort; HC) revealed a 20% incidence of new-onset posttransplantation diabetes mellitus (PTDM) and 32% with impaired glucose tolerance (IGT) or impaired fasting glucose (IFG). We examined whether glucose tolerance has improved after recent changes in our immunosuppressive protocol and a switch from deferred to preemptive cytomegalovirus (CMV) therapy. METHODS: A total of 321 consecutive, nondiabetic patients (new cohort; NC) were examined 10 weeks after kidney transplantation with an oral glucose tolerance test (n=301) between January 2004 and December 2005. RESULTS: Although recipients in the NC were on average 3 years older [mean (SD): 50.3 (14.6) vs. 47.4 (16.0), P=0.038] and had a higher mean body mass index [24.5 (3.6) vs. 23.5 (3.8) kg/m(2), P=0.003], a significantly lower incidence of both PTDM (13%) and IGT/IFG (18%) was observed in the NC (P<0.001) as compared to the HC. The patients in the NC received a significantly lower mean daily oral prednisolone dose [13.2 (4.7) vs. 15.3 (6.6) mg/day, P<0.001], and had lower frequencies of rejections (36% vs. 57%, P<0.001) and CMV infection (54% vs. 63%, P=0.071). Patients in the NC had significantly lower odds of developing PTDM, even after adjustment for age, prednisolone dose, HLA-B27 status and CMV infection (odds ratio: 0.42, 95% CI: 0.23-0.77, P=0.005). CONCLUSIONS: The odds of developing PTDM are more than halved over the last decade. Possible explanations are changes in immunosuppressive therapy, fewer rejections, and lower doses of steroids.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis and Classification of Diabetes Mellitus
American Diabetes Association (2006) · Diabetes Care · doi:10.2337/diacare.29.s1.06.s43 · Cited by 924
Heisel, O., Heisel, R., Balshaw, R., & Keown, P. (2004) · American Journal of Transplantation · doi:10.1046/j.1600-6143.2003.00372.x · Cited by 506 · cited 1×
“Increasing evidence indicates that tacrolimus is more diabetogenic than CsA (3, 7, 11), and high dose tacrolimus during the first month after transplantation is associated with PTDM (33).”
Background
Cited by
Post-transplant diabetes mellitus in patients with solid organ transplants
Jenssen, T., & Hartmann, A. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0137-7 · Cited by 278
Self-citationHalden, T. A. S., Kvitne, K. E., Midtvedt, K., Rajakumar, L., Robertsen, I., Brox, J., Bollerslev, J., Hartmann, A., Åsberg, A., & Jenssen, T. (2019) · Diabetes Care · doi:10.2337/dc19-0093 · Cited by 231
Self-citationStrom Halden, T. A., Asberg, A., Vik, K., Hartmann, A., & Jenssen, T. (2014) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gft536 · Cited by 89
Self-citationImpaired glucose homeostasis in renal transplant recipients receiving basiliximab
Aasebo, W., Midtvedt, K., Valderhaug, T. G., Leivestad, T., Hartmann, A., Reisaeter, A. V., Jenssen, T., & Holdaas, H. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfp617 · Cited by 38
Self-citation
Metadata
- Authors
- Valderhaug, T. G., Hjelmesæth, J., Rollag, H., Leivestad, T., Røislien, J., Jenssen, T., & Hartmann, A.
- Venue
- Transplantation
- Published
- 2007-11-15
- Volume
- 84
- Issue
- 9
- Pages
- 1125-1130
- ISSN
- 0041-1337 (ISSN-L)
- OpenAlex
- W1986729011
- Cited by
- 70
- References
- 3
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Reduced Incidence of New-Onset Posttransplantation Diabetes Mellitus During the Last Decade. https://app.cochat.ai/papers/10.1097/01.tp.0000287191.45032.38
- The paper
- Valderhaug, T. G., Hjelmesæth, J., Rollag, H., Leivestad, T., Røislien, J., Jenssen, T., & Hartmann, A. (2007). Reduced Incidence of New-Onset Posttransplantation Diabetes Mellitus During the Last Decade. Transplantation. https://doi.org/10.1097/01.tp.0000287191.45032.38
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.